3.06
0.0496 (1.65%)
0.0496 (1.65%)
Upgrade to Real-Time
Regular Market
Volume | 29,593 |
|
|||||
News | (1) | ||||||
Day High | 3.28 | Low High |
|||||
Day Low | 3.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioRestorative Therapies Inc | BRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.04 | 3.02 | 3.28 | 3.0104 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
222 | 29,593 | $ 3.09 | $ 91,524 | - | 2.46 - 5.975 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:28:23 | 100 | $ 3.06 | USD |
BioRestorative Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 11.24M | 3.67M | 2.85M | $ 46.00k | $ - | -38.33 | -0.20 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 4.94k | 21.80% |
BioRestorative Therapies News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.02 | 3.32 | 2.85 | 3.10 | 9,830 | 0.04 | 1.32% |
1 Month | 3.00 | 3.32 | 2.85 | 3.06 | 6,182 | 0.06 | 2.0% |
3 Months | 3.00 | 4.40 | 2.55 | 3.20 | 15,155 | 0.06 | 2.0% |
6 Months | 3.46 | 4.40 | 2.46 | 3.15 | 13,300 | -0.40 | -11.56% |
1 Year | 3.79 | 5.975 | 2.46 | 4.19 | 24,079 | -0.73 | -19.26% |
3 Years | 8.90 | 8.90 | 2.46 | 5.00 | 109,757 | -5.84 | -65.62% |
5 Years | 8.90 | 8.90 | 2.46 | 5.00 | 109,757 | -5.84 | -65.62% |
BioRestorative Therapies Description
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |